drugset / Trial / NCT07005284
A Study of LY3981314 in Healthy Participants
RandomizedParallel-groupDouble-blindBasic science
Summary
The main purpose of this study is to investigate the safety of LY3981314 when administered subcutaneously (SC) (under the skin), and how it's processed in the body. The study will last approximately 25 weeks, excluding a screening period with an optional extension to approximately 49 weeks for qualifying participants.
Timeline
- Start
- 2025-06-09
- Primary completion
- 2027-02
- Completion
- 2027-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY3981314 | Unknown | — | Subcutaneous |
Indications
No indication recorded.